Merck Cuts Full-Year Revenue Projection Despite Strong Q2 Performance
Merck lowered its full-year revenue forecast due to acquisition costs, despite a strong second quarter with growth in key therapies like Winrevair and Capvaxive, and a rise in animal health and Keytruda sales.